Mosaed Reza, Fasihi Hossein, Norouzi Amir, Anjomanian Vahid, Ardalan Mohammad Afshar, Alazmani Noodeh Farshid, Khoshdel Ali Reza
Department of Clinical Pharmacy, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Biomaterial and Medicinal Chemistry Research Center, AJA University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2022 May 29;21(1):e127032. doi: 10.5812/ijpr-127032. eCollection 2022 Dec.
The COVID-19 pandemic has prompted researchers to find treatments and vaccines to control SARS-CoV-2. There are some hypotheses about the benefit of respiratory virus vaccines, like MMR, for COVID-19 pneumonia severity, morbidity, and mortality. The influenza vaccine is one of the most frequently used respiratory virus vaccines covered by one of the Iranian insurance institutes. We have a symmetrical group of participants that have received this vaccine that could be compared with each other. We compared 3,379 persons aged 20 - 75 years for the effect of the influenza vaccine on COVID-19 mortality. We ultimately found that it does not affect mortality caused by COVID-19 pneumonia, but it can decrease the hospitalization cost in people over 65 years with a history of chronic disease.
新冠疫情促使研究人员寻找控制新冠病毒(SARS-CoV-2)的治疗方法和疫苗。关于如麻疹、腮腺炎、风疹(MMR)等呼吸道病毒疫苗对新冠肺炎严重程度、发病率和死亡率的益处,存在一些假说。流感疫苗是伊朗一家保险机构承保的最常用呼吸道病毒疫苗之一。我们有一组对称的接种了该疫苗的参与者,他们之间可以相互比较。我们比较了3379名年龄在20至75岁之间的人,以研究流感疫苗对新冠死亡率的影响。我们最终发现,它不会影响新冠肺炎导致的死亡率,但可以降低65岁以上有慢性病病史人群的住院费用。